Abstract
Introduction: In the last one decade first generation tyrosine kinase inhibitor (TKI), imatinib mesylate was the choice of treatment in Chronic Myeloid Leukemia (CML) but recently, a considerable number of patients have developed resistance to first as well as second generation TKIs.
 Objective: To present two cases which were first and second generation TKIs resistant and to review multidrug resistant CML.
 Materials and Methods: Relevant articles and literatures were retrieved from different journals and web pages to find out the mechanism of development of drug resistance in chronic myeloid leukaemia.
 Discussion: Two cases of drug resistant CML were found in Combined Military Hospital (CMH), Dhaka cantonment. Extensive review of the literature showed that two mechanisms, namely Breakpoint Cluster Region-Abelson (BCR-ABL) dependent and independent mechanisms, are mainly responsible for multi drug resistant (MDR) CML. In Bangladesh, it is difficult to identify the exact mechanism of development of drug resistance in CML. In a few cases, sample from CML patients are sent overseas to detect any new mutation in TKI binding domain of BCR – ABL fusion gene but it is not possible to find out other mechanisms responsible for drug resistance in CML.
 Conclusion: To overcome the drug resistance in CML, it is important to use the conventional drugs used in the treatment of CML meticulously and regularly as irregular use and discontinuation of treatment will permit the development of drug resistance.
 Journal of Armed Forces Medical College Bangladesh Vol.12(2) 2016: 135-140
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Armed Forces Medical College, Bangladesh
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
